Signaturefd LLC Purchases 3,561 Shares of Mesoblast Limited (NASDAQ:MESO)

Signaturefd LLC raised its position in shares of Mesoblast Limited (NASDAQ:MESO) by 64.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,067 shares of the company’s stock after purchasing an additional 3,561 shares during the period. Signaturefd LLC’s holdings in Mesoblast were worth $180,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of MESO. Jane Street Group LLC increased its holdings in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after acquiring an additional 26,959 shares during the period. GAMMA Investing LLC increased its holdings in shares of Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after acquiring an additional 1,213 shares during the period. Ballentine Partners LLC purchased a new position in shares of Mesoblast in the 4th quarter valued at $222,000. R Squared Ltd purchased a new position in shares of Mesoblast in the 4th quarter valued at $30,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Mesoblast in the 4th quarter valued at $134,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Stock Up 1.9 %

Shares of MESO stock opened at $13.94 on Friday. Mesoblast Limited has a 1-year low of $2.08 and a 1-year high of $22.00. The stock’s fifty day moving average price is $16.66 and its 200 day moving average price is $12.90. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Mesoblast presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.